Clinical Trial Update: A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Cixutumumab (IMC-A12) with or without standard chemotherapies in patients with treatment-naive non-small cell lung cancer; the trial is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMC-A12 (cixutumumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-06-01